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In vitro Kinase Selectivity for 16. compartments were determined by LC-MS/MS analysis. The apparent permeability (P app ), in the apical to A-B and B-A directions, was calculated after a 2-hour incubation as:
Where: dQ/dt = rate of compound appearance in the receiver compartment; A = Surface area of the insert; C 0 = Initial substrate concentration at T0.
The efflux ratio (ER) was calculated as (P app, B-A /P app, A-B ).
All efflux ratios reported represent the arithmetic mean of a minimum of at least two determinations and these assays generally produced results within 50% of the reported mean.
Determination of plasma protein and brain binding. The extent of protein binding was determined in vitro, in mouse plasma (Bioreclamation, Inc., Hicksville, NY) by equilibrium dialysis using a HTDialysis 96-well block (HTDialysis  LLC; Gales Ferry, CT). The compound was added to pooled plasma from multiple animals (n ≥ 3) at a total concentration of 10 µM.
Plasma samples were equilibrated with phosphate-buffered saline (pH 7.4) at 37°C in 90% humidity and 5% CO 2 for 4 hours. Following dialysis, concentration of compounds in plasma and buffer were measured by LC-MS/MS. The percent unbound in plasma was determined by dividing the concentration measured in the post-dialysis buffer by that measured in the postdialysis plasma and multiplying by 100. Incubations were performed in triplicate and coefficient of variation is not greater than 30%.
The free fraction in mouse brain was determined as described by Kalvass. 2 Briefly, brain tissue was homogenized in 3 volumes of phosphate-buffered saline and compound was added at a final concentration of 10 µM. Aliquots of 300 µl were dialyzed in a RED device (Thermo Scientific, Rockford, IL) against a volume of 500 µl buffer for 4 h at 37ºC in an incubator at 90% humidity and 5% CO 2. . Following dialysis, tissues and buffer samples were analyzed as described for the plasma protein binding studies. also employed using R to analyze the repeated measurement of body weight changes from the same animals over time.
Chemistry 2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol (12).
4-(2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine 3 (10, 25.0 g, 0.08 mol) was cooled to -78 ºC in THF (400 mL). A solution of n-butyllithium (2.5 M in hexanes, 62 mL, 0.15 mol) was added portion-wise over 10 min. The mixture gradually turned yellow. The reaction mixture stirred at -78 ºC for 15 min, then anhydrous acetone (12.5 mL, 0.17 mol) was added.
The resulting reaction mixture was slowly warmed to 0 ºC over a 2 hour period. The mixture was subsequently quenched with water, extracted with EtOAc and dried over MgSO 4 . The slurry was filtered and concentrated in vacuo to provide 2-(2-chloro-6-morpholino-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-8-yl)propan-2-ol. The crude material was taken up in MeOH (530 mL) and ptoluenesulfonic acid (1.3 g, 0.008 mol) was added. The reaction mixture was heated to 50 ºC for 30 min. The reaction mixture was concentrated, rinsed with excess water and filtered to dryness to provide 12 (21.6 g, 94% over 2 steps). 
4-methyl-5-(4, 4, 5, 5-tetramethyl (1, 3, 2-dioxaborolan-2-yl)) pyrimidine-2-ylamine (17).
To a solution of 4-methylpyrimidine-2-ylamine (8.0 g, 0.073 mol) in chloroform (320 mL) was added N-bromosuccinimide (13.7 g, 0.077 mol). The reaction mixture was stirred in the dark for 18 hrs. LC/MS indicated the reaction was completed. The mixture was diluted with DCM, then washed with 1N NaOH aq solution and brine, dried over MgSO 4 , filtered and concentrated to yield 5-bromo-4-methylpyrimidine-2-ylamin (12 g, Yield: 86%).
4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (18).
A mixture of 5-bromo-4-methylpyrimidine-2-ylamine (5.0g, 26 mmol), potassium acetate (7. 
2-(2-(2-amino-4-methylpyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholino-9H-purin-8-yl)propan-2-ol (4).
2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol (12, 10 g, 0.03 mol) was dissolved in DMF (20 mL). 2-Bromoethyl acetate (11.1 mL, 0.1 mol) and cesium carbonate (21.9 g, 0.07 mol)
were added and the reaction mixture was heated to 50 ºC for several hours. After quenching with water, the reaction mixture was extracted with EtOAc and concentrated. The crude reaction mixture was purified by silica gel chromatography (gradient of 0-50% EtOAc in hexane). The resulting 2-(2-chloro-8-(2-hydroxypropan-2-yl)-6-morpholino-9H-purin-9-yl)ethyl acetate was treated with 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (18, 14.5 g, 0.07 mol) and PdCl 2 Ph 2 (1.8 g, 2.5 mmol) in 1 M Na 2 CO 3 (100 mL) and CH 3 CN (100 mL). The reaction mixture was divided into 10 equal batches and each was microwaved at 300 watts, 140 ºC for 15 min. All batches were then combined and concentrated then taken up into iPrOH (20 mL) and heated to reflux. After then cooling to RT the resulting solid was filtered to provide 2-(2-(2-amino-4-methylpyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholino-9H-purin-8-yl)propan-2-ol (4, 4.6 g, 37% over 2 steps 
5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5).
2-chloro-9-methyl-6-morpholin-4-yl-9H-purine 3 
4-(2-chloro-8-iodo-9-methyl-9H-purin-6-yl)morpholine (19).
A suspension of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (2.95 g, 11.7 mmol) and TMEDA (2.6 mL, 2.03 g, 17.5 mmol) in THF (80 mL) was cooled to -78 ºC before the drop wise addition of n-BuLi (9.8 mL, 24.5 mmol, 2.5 M solution in hexanes). The resulting mixture was warmed to -40 ºC and stirred 40 mins. The mixture was cooled back to -78 ºC before the addition of 1-chloro-2-iodoethane (3.7 mL, 7.8 g, 40.8 mmol). The resulting mixture was allowed to warm to r.t. over a 2 h period then quenched with NH 4 Cl and extracted with EtOAc (×4). The combined organics were dried (Na 2 SO 4 ) and concentrated in vacuo affording the title compound as a yellow solid (4.02 g, 91%). LCMS: R T 4.09 min, m/z = 379.9 [M+H] + .
4-(2-chloro-8-ethyl-9-methyl-9H-purin-6-yl)morpholine (20).
4-(2-chloro-8-iodo-9-methyl-9H-purin-6-yl)morpholine (19, 0.20 g, 0.53 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride (6.5 mg, 0.008 mmol) were dissolved in 1,4-dioxane (2.634 mL). 1.0 M of diethyl zinc in hexane (1.1 mL, 1.1 mmol) was added drop wise to the reaction mixture. The reaction was stirred at 60 °C for 2.5h, then cooled to ambient temperature. MeOH was then added drop wise, and the volatiles removed in vacuo. The crude residue was diluted with 1N HCl, water, brine and EtOAc. The layers were separated and the aqueous phase was extracted into EtOAc (×3), dried over Na 2 SO 4 , filtered and absorbed onto Celite for purification by flash column chromatography [12 g column, 0-80% EtOAc/heptanes over 18 min] to afford the title compound as a light yellow solid (106 mg, 72%).
5-(8-ethyl-9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (6).
A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 20 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used to generate this compound. 
4-(2-chloro-8-cyclobutyl-9-methyl-9H-purin-6-yl)morpholine (21).
4-(2-chloro-8-iodo-9-methyl-9H-purin-6-yl)morpholine (0.5 g, 1.32 mmol), potassium cyclobutyltrifluoroborate (320 mg, 1.98 mmol), Cs 2 CO 3 (1.3 g, 3.95 mmol), and Pd(OAc) 2 (6 mg, 0.03 mmol) were suspended in toluene (4.8 mL) and heated at 100 °C overnight. The reaction mixture was cooled to ambient temperature and diluted with saturated aqueous sodium bicarbonate, water, brine and EtOAc. The layers were separated and the aqueous phase was extracted into EtOAc (3x), dried over Na 2 SO 4 , filtered and absorbed onto Celite for purification via FCC [80 g, 0-50% EtOAc/heptanes] to afford 64 mg (16%) of the title compound.
5-(8-cyclobutyl-9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (7).
A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 21 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used was used to generate this compound. 1 
3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)oxetan-3-ol (22).
To 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine (1.50 g, 5.93 mmol) in THF (48 mL) at -48 °C was added 2.5 M of n-butyllithium in hexanes (6.6 mL, 16.6 mmol) and stirred for 30 min.
Following this, 3-oxetanone (1.1 mL, 23.7 mmol) was added and the reaction mixture was stirred for 2 h. The mixture was quenched with water and extracted with EtOAc. The combined organics were dried over Na 2 SO 4 , filtered and absorbed onto Celite for purification via FCC [80g, 0-100% EtOAc in heptanes] to afford the title compound as a white solid (1.32 g, 68%).
3-(2-(2-aminopyrimidin-5-yl)-9-methyl-6-morpholino-9H-purin-8-yl)oxetan-3-ol (8).
A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 22 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used was used to generate this compound. 
4-(2-chloro-8-(3-methoxyoxetan-3-yl)-9-methyl-9H-purin-6-yl)morpholine (23).
A solution of 3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)oxetan-3-ol (0.5 g, 1.54 mmol)
in DMF (8.3 mL) was cooled to 0 ºC. NaH (60% dispersion in oil, 185 mg, 7.70 mmol) was added in one portion. The reaction mixture was stirred for 5 minutes and resulted in a dark orange hue. Methyl iodide (0.29 mL, 4.62 mmol) was added and the reaction mixture was allowed to warm to ambient temperature and stirred 2 h. The reaction was diluted with saturated aqueous Na 2 CO 3 solution and extracted into EtOAc. The combined organics were dried over Na 2 SO 4 , filtered and absorbed onto Celite for purification via FCC (80 g column, 0-100% EtOAc in heptane) to afford the title compound as a white solid (505 mg, 96%).
5-(8-(3-methoxyoxetan-3-yl)-9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (9).
A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 23 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used was used to generate this compound. 
